Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate https://lnkd.in/egwxrE3y
Monopar Therapeutics Inc.
生物技术研究
Wilmette，Illinois 1,976 位关注者
Striving to develop proprietary therapeutics to extend life or improve quality of life for cancer patients. Nasdaq: MNPR
关于我们
Monopar Therapeutics is a clinical--stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma? MNPR-101, a late--stage preclinical antibody for radiopharmaceutical use in advanced cancers? and MNPR-202, an early-stage camsirubicin analog for various cancers.?
- 网站
-
https://www.monopartx.com/
Monopar Therapeutics Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Wilmette，Illinois
- 类型
- 上市公司
- 创立
- 2015
地点
-
主要
获取路线
1000 Skokie Blvd
US，Illinois，Wilmette，60091
Monopar Therapeutics Inc.员工
动态
-
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Radiopharma Program at EANM 2024 https://lnkd.in/gcYzHmJD
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
ir.monopartx.com
-
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers https://lnkd.in/gAeqvN-q
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
globenewswire.com
-
Updated Monopar Corporate Presentation with the recent Phase 1 Human Imaging Data: https://lnkd.in/gWsn2WdQ
Presentations
ir.monopartx.com
-
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr https://lnkd.in/ggsv-6Y4
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
globenewswire.com
-
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers https://lnkd.in/gP-ygq5J.
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
globenewswire.com
-
Monopar and NorthStar Amend & Extend Collaboration https://lnkd.in/gxQnyjky
Monopar and NorthStar Amend & Extend Collaboration
globenewswire.com
-
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting https://lnkd.in/gpuFE3DN
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
globenewswire.com
-
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients https://lnkd.in/gkc-KvKH
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
globenewswire.com
-
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients https://lnkd.in/gkc-KvKH
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
globenewswire.com